Sarantis: Tough Q2 2026; 2028 Targets Intact, but Patience Required
Q2 was weak, with sales down 0.7% yoy, adjusted* EBITDA down -13% and adjusted EBIT down -15%, with EBIT margin contracting 210bps yoy. On an H1 basis, the phasing of selected international sales and continued weakness in Romania and Ukraine resulted in a E3.1m EBIT drag, only partly offset by Poland, Bulgaria and Czech /Slovakia/Hungary.